Fortgeschrittenes nichtkleinzelliges Lungenkarzinom
详细信息 查看全文
- 作者：PD Dr. W. Schütte (1)
S. Nagel (1)
G. Haak (1)
M. Steinert (2) - 关键词：Lungenkrebs ; Erhaltungstherapie ; Second ; line ; Therapie ; Chemotherapie ; Target ; Therapie ; Lung cancer ; Maintenance treatment ; Second ; line therapy ; Chemotherapy ; Targeted therapy
- 刊名：Der Pneumologe
- 出版年：2012
- 出版时间：January 2012
- 年：2012
- 卷：9
- 期：1
- 页码：43-48
- 全文大小：430KB
- 参考文献：1. Azzoli CG, Baker S Jr et al (2009) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251-266 CrossRef
2. Belani CP, Waterhouse DM, Ghazal H et al (2010) Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 28:15 (suppl; abstr 7506) CrossRef
3. Brodowicz T, Krzakowski M, Zwitter M et al (2006) Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52:155-63 CrossRef
4. Cappuzzo F, Ciuleanu T, Stelmakh L et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-29 CrossRef
5. Ciuleanu T, Brodowicz T, Zielinski C et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374:1432-440 CrossRef
6. Ciuleanu T, Stelmakh L, Cicenas S et al (2011) Efficacy of second-line erlotinib versus chemotherapy relative to biomarker status in the phase III global TITAN study in advanced non-small-cell lung cancer (NSCLC). WCLC 2011 (abstr. 1058)
7. Fidias PM, Dakhil SR, Lyss AP et al (2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27:591-98 CrossRef
8. Fossella FV, DeVore R, Kerr RN et al (2010) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-362
9. Kuo CH, Lin SM, Lee KY et al (2010) Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance. Clin Lung Cancer 11:51-6 CrossRef
10. Di Maio M, Perrone F, Chiodini P et al (2007) Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 25:1377-382 CrossRef
11. Paz-Ares F, De Marinis M, Dediu M et al (2011) PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 29:(suppl. abstr 7510)
12. Perol M, Chouaid C, Milleron BJ et al (2010) Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol. 28:15 (suppl; abstr 7507)
13. Reck M, von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227-234 CrossRef
14. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-550 CrossRef
15. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C et al (2005) Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23:8389-395 CrossRef
16. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-103
17. Yamamoto N, Katakami N, Atagi S et al (2011) A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G). J Clin Oncol 29:(suppl; abstr 7524) - 作者单位：PD Dr. W. Schütte (1)
S. Nagel (1)
G. Haak (1)
M. Steinert (2)
1. Klinik für Innere Medizin II, Krankenhaus Martha-Maria Halle-D?lau, R?ntgenstr. 1, 06120, Halle, Deutschland
2. Klinik für Thoraxchirurgie, Krankenhaus Martha-Maria Halle-D?lau, Halle, Deutschland
文摘
Maintenance and second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) have become a standard of care. Optimal conditions for maintenance treatment are both specific analysis of tumor histology and choice of first-line treatment. This includes evaluation of EGFR mutation status, histology of the tumor, and response to first-line treatment. Immediately after first-line therapy continuous as well as switch maintenance treatment are available so far. When patients express a preference, the indication has to be considered. Chemotherapy agents of continuous treatment are pemetrexed and docetaxel as well as tyrosine kinase inhibitors, bevacizumab, and cetuximab. Recommendations in the second-line setting are pemetrexed, docetaxel, or erlotinib as the standard. The choice of second-line treatment depends on first-line therapy and their toxicities. After first-line therapy with a tyrosine kinase inhibitor platinum-based chemotherapy with a taxane is indicated. By carefully considering treatment and patient characteristics, the therapeutic procedure has become a distinctly improved setting due to the development of new therapeutic possibilities in recent years.